RevitalVision Demonstrates Efficacy, Safety in Infantile Nystagmus

Positive clinical data shows improvement in visual function in patients with infantile nystagmus

By
Conexiant News Staff
January 13, 2026
1 min

Optometric Management

Objective:

To evaluate the efficacy and safety of RevitalVision, a digital therapeutic treatment for infantile nystagmus.

Approach:

Key Findings:

RevitalVision is the first FDA-cleared neuroplasticity-based visual training program for infantile nystagmus.
The study provides randomized controlled evidence of improved visual function in patients.

Interpretation:

The findings suggest that RevitalVision may be a viable treatment option for enhancing visual function in individuals with infantile nystagmus.

Conclusion:

The positive clinical data supports the use of RevitalVision as an effective treatment for improving visual function in patients with infantile nystagmus.